AZ-960

• CAT Number: I003500
• CAS Number: 905586-69-8
• Molecular Formula: C18H16F2N6
• Molecular Weight: 354.40
• Purity: ≥95%
• Synonyms: AZ960; AZ 960; AZ-960.;(S)-5-fluoro-2-(1-(4-fluorophenyl)ethylamino)-6-(5-methyl-1H-pyrazol-3-ylamino)nicotinonitrile
• Target: JAK
• Solubility: Soluble in DMSO, not in water
• Storage: 0 - 4 °C for short term or -20 °C for long term
• IUPAC Name: 5-fluoro-2-[[(1S)-1-(4-fluorophenyl)ethyl]amino]-6-[(5-methyl-1H-pyrazol-3-yl)amino]pyridine-3-carbonitrile
• InChI: InChI=1S/C18H16F2N6/c1-10-7-16(26-25-10)23-18-15(20)8-13(9-21)17(24-18)22-11(2)12-3-5-14(19)6-4-12/h3-8,11H,1-2H3,(H3,22,23,24,25,26)/t11-/m0/s1
• InChIKey: SUNXHXDJOIXABJ-NSHDSACASA-N
• SMILES: CC1=CC(=NN1)NC2=C(C=C(C(=N2)N[C@@H](C)C3=CC=C(C=C3)F)C#N)F

AZ-960（Cat No.:I003500）is a selective inhibitor of the protein kinase B (Akt), specifically targeting the Akt1 isoform. By inhibiting Akt, AZ-960 disrupts key signaling pathways involved in cell proliferation, survival, and metabolism, making it a valuable tool in cancer research. This compound has demonstrated potential in preclinical studies to reduce tumor growth and enhance the effects of other therapeutic agents. Additionally, AZ-960 is being explored for its ability to modulate metabolic pathways, positioning it as a promising candidate for developing targeted therapies in cancers characterized by aberrant Akt signaling.

Reference

1: Ikezoe T, Kojima S, Furihata M, Yang J, Nishioka C, Takeuchi A, Isaka M, Koeffler HP, Yokoyama A. Expression of p-JAK2 predicts clinical outcome and is a potential molecular target of acute myelogenous leukemia. Int J Cancer. 2011 Nov 15;129(10